Abbott (NYSE: ABT) + today said that it completed a public offering of senior notes worth $20 billion in total. The company ...

Exact SciencesEXAS stock crashed to a three-year low Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer test. The company already developed a blood-based ...

Exact Sciences’ (NDAQ: EXAS) history is a tale of two halves. Founded in 1995 in Marlborough, Massachusetts, “Exact,” as the company is known, went public in 2001 but struggled to find its footing, ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% ...

Exact Sciences is seeing consistent revenue growth in the low teens, driven by its flagship Cologuard test and expanding precision oncology offerings. Analysts are solidly bullish, with 15 analyst ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® ...

Exact Sciences Corp (NASDAQ:EXAS) shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the details from the report. The Details: Exact ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 ...

Exact Sciences Corporation EXAS is well poised for growth in the coming quarters, led by Cologuard growth. It is progressing well with its strategic prioritization, likely to drive the company’s ...

Subscribe to BizTimes Daily – Local news about the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin. Madison-based Exact Sciences, a maker and provider of cancer ...